<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02298491</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00062490</org_study_id>
    <nct_id>NCT02298491</nct_id>
  </id_info>
  <brief_title>CNS Sarcoidosis and Acthar Gel</brief_title>
  <official_title>Clinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar Gel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if treatment with H.P. Acthar® Gel will result in the&#xD;
      improvement and long-term stabilization of clinical and radiographic abnormalities that occur&#xD;
      in patients with CNS sarcoidosis. In addition, it will also look at whether treatment will be&#xD;
      also associated with improvement in measures of quality of life. The treatment of CNS&#xD;
      sarcoidosis involves the use of either corticosteroids such as prednisone or potent&#xD;
      immunosuppressive agents such as methotrexate, both which can induce severe long term side&#xD;
      effects. The adverse effects of steroids may be avoided by treatment with adrenocorticotropic&#xD;
      hormone (ACTH), which is available for patient use as H.P. Acthar® Gel. The efficacies of&#xD;
      H.P. Acthar® Gel in the treatment of CNS sarcoidosis and the impact on quality of life have&#xD;
      not been previously studied. In addition, little is known regarding the expression of immune&#xD;
      markers in CNS sarcoidosis and the association of such markers with disease activity and&#xD;
      response to treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sarcoidosis is a chronic and frequently progressive systemic disease that affects the central&#xD;
      nervous system (CNS) in approximately 5% of patients. The hallmark of the disease is the&#xD;
      development of chronic inflammation with formation of non-caseating granulomas that can&#xD;
      involve the brain parenchyma and meninges and appear as contrast-enhancing mass lesions on&#xD;
      magnetic resonance imaging. The granulomas are primarily comprised of proinflammatory T cells&#xD;
      (Th1 cells and Th17 cells) and macrophages which accumulate during the early stages of&#xD;
      granuloma formation. The inflammation that is generated by these cells is modulated by&#xD;
      anti-inflammatory responses mediated by Th2 cells and regulatory T (Treg) cells that later&#xD;
      appear and populate the outer regions of the granuloma. The presence of Treg cells are of&#xD;
      particular interest since these cell are also detected in high numbers in peripheral blood&#xD;
      and the immune suppression that results may underlie the occurrence of anergy in patients&#xD;
      with the disease. The treatment of CNS sarcoidosis involves the use of either corticosteroids&#xD;
      or potent immunosuppressive agents, both which can induce severe long-term side effects. The&#xD;
      adverse effects of steroids may be avoided by treatment with adrenocorticotropic hormone&#xD;
      (ACTH), which is available for patient use as H.P. Acthar® Gel. The efficacy of H.P. Acthar®&#xD;
      Gel in the treatment of CNS sarcoidosis and the impact on quality of life have not been&#xD;
      previously examined. In addition, little is known regarding the expression of immune markers&#xD;
      in CNS sarcoidosis and the association of such markers with disease activity and response to&#xD;
      treatment. These issues, therefore, will be explored in the context of this proposal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">November 2020</completion_date>
  <primary_completion_date type="Actual">November 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Lesions</measure>
    <time_frame>1 year</time_frame>
    <description>Total number of lesions assessed at 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Measures</measure>
    <time_frame>4 weeks, 6 months and 12 months</time_frame>
    <description>Change in Patient Determined Disease Steps (PDDS), Montreal Cognitive Assessment (MoCA), Symbol-Digit Modalities Test (SDMT), Short Form -36 Health Survey (SF-36), Work Productivity and Activities Impairment -General Health (WPAI-GH) and Beck Depression Inventory-II (BDI-II) at 4 weeks, 6 months and 12 months relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Measure</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Treatment Satisfaction Questionnaire for Medication (TSQM) scores at 4 weeks and change in TSQM scores at 6 months and 12 months versus baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum and Cerebrospinal Fluid Immune Markers</measure>
    <time_frame>4 weeks, 6 months and 12 months</time_frame>
    <description>Change in levels of serum and cerebrospinal fluid immune markers at 4 weeks, 6 months and 12 months versus baseline</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>CNS Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>H.P. Acthar Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H.P. Acthar Gel</intervention_name>
    <description>80 IU subcutaneously daily for 10 days then followed by 80 IU subcutaneously three times per week through Month 12</description>
    <arm_group_label>H.P. Acthar Gel</arm_group_label>
    <other_name>ACTH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A highly probable diagnosis of sarcoidosis, as determined using the World Association&#xD;
             for Sarcoidosis and Other Granulomatous Disorders (WASOG) Sarcoidosis Organ Assessment&#xD;
             Instrument (Judson et al., 2014), with involvement not limited to the central nervous&#xD;
             system.&#xD;
&#xD;
          -  At the time of enrollment, a history of clinical deterioration based on the&#xD;
             development of new symptoms or worsening previously present symptoms with confirmation&#xD;
             by clinical examination and objective clinical testing.&#xD;
&#xD;
          -  If on steroids, on a stable dose of the medication for at least 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Horea Rus</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland, Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Agostini C, Meneghin A, Semenzato G. T-lymphocytes and cytokines in sarcoidosis. Curr Opin Pulm Med. 2002 Sep;8(5):435-40. Review.</citation>
    <PMID>12172449</PMID>
  </reference>
  <reference>
    <citation>Arnason BG, Berkovich R, Catania A, Lisak RP, Zaidi M. Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Mult Scler. 2013 Feb;19(2):130-6. doi: 10.1177/1352458512458844. Epub 2012 Oct 3. Review.</citation>
    <PMID>23034287</PMID>
  </reference>
  <reference>
    <citation>Co DO, Hogan LH, Il-Kim S, Sandor M. T cell contributions to the different phases of granuloma formation. Immunol Lett. 2004 Mar 29;92(1-2):135-42. Review.</citation>
    <PMID>15081537</PMID>
  </reference>
  <reference>
    <citation>Judson MA, Costabel U, Drent M, Wells A, Maier L, Koth L, Shigemitsu H, Culver DA, Gelfand J, Valeyre D, Sweiss N, Crouser E, Morgenthau AS, Lower EE, Azuma A, Ishihara M, Morimoto S, Tetsuo Yamaguchi T, Shijubo N, Grutters JC, Rosenbach M, Li HP, Rottoli P, Inoue Y, Prasse A, Baughman RP, Organ Assessment Instrument Investigators TW. The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis. 2014 Apr 18;31(1):19-27.</citation>
    <PMID>24751450</PMID>
  </reference>
  <reference>
    <citation>Miller DH, Kendall BE, Barter S, Johnson G, MacManus DG, Logsdail SJ, Ormerod IE, McDonald WI. Magnetic resonance imaging in central nervous system sarcoidosis. Neurology. 1988 Mar;38(3):378-83.</citation>
    <PMID>3347340</PMID>
  </reference>
  <reference>
    <citation>Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, Kambouchner M, Valeyre D, Chapelon-Abric C, Debré P, Piette JC, Gorochov G. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med. 2006 Feb 20;203(2):359-70. Epub 2006 Jan 23. Erratum in: J Exp Med. 2006 Feb 20;203(2):477.</citation>
    <PMID>16432251</PMID>
  </reference>
  <reference>
    <citation>Moller DR. Treatment of sarcoidosis -- from a basic science point of view. J Intern Med. 2003 Jan;253(1):31-40. Review.</citation>
    <PMID>12588536</PMID>
  </reference>
  <reference>
    <citation>Royal W 3rd, Mia Y, Li H, Naunton K. Peripheral blood regulatory T cell measurements correlate with serum vitamin D levels in patients with multiple sclerosis. J Neuroimmunol. 2009 Aug 18;213(1-2):135-41. doi: 10.1016/j.jneuroim.2009.05.012. Epub 2009 Jun 17.</citation>
    <PMID>19539379</PMID>
  </reference>
  <reference>
    <citation>Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 2011 Oct 10;11(11):762-74. doi: 10.1038/nri3070. Review.</citation>
    <PMID>21984070</PMID>
  </reference>
  <reference>
    <citation>Stern BJ, Aksamit A, Clifford D, Scott TF; Neurosarcoidosis Study Group. Neurologic presentations of sarcoidosis. Neurol Clin. 2010 Feb;28(1):185-98. doi: 10.1016/j.ncl.2009.09.012.</citation>
    <PMID>19932381</PMID>
  </reference>
  <reference>
    <citation>Stern BJ, Krumholz A, Johns C, Scott P, Nissim J. Sarcoidosis and its neurological manifestations. Arch Neurol. 1985 Sep;42(9):909-17. Review.</citation>
    <PMID>3896208</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 14, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2014</study_first_posted>
  <results_first_submitted>November 24, 2020</results_first_submitted>
  <results_first_submitted_qc>January 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 4, 2021</results_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Horea Rus</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 30, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT02298491/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>H.P. Acthar Gel</title>
          <description>H.P. Acthar Gel: 80 IU subcutaneously daily for 10 days then followed by 80 IU subcutaneously three times per week through Month 12</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>H.P. Acthar Gel</title>
          <description>H.P. Acthar Gel: 80 IU subcutaneously daily for 10 days then followed by 80 IU subcutaneously three times per week through Month 12</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.3" lower_limit="40" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Lesions</title>
        <description>Total number of lesions assessed at 1 year</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>H.P. Acthar Gel</title>
            <description>H.P. Acthar Gel: 80 IU subcutaneously daily for 10 days then followed by 80 IU subcutaneously three times per week through Month 12</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Lesions</title>
          <description>Total number of lesions assessed at 1 year</description>
          <units>lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Measures</title>
        <description>Change in Patient Determined Disease Steps (PDDS), Montreal Cognitive Assessment (MoCA), Symbol-Digit Modalities Test (SDMT), Short Form -36 Health Survey (SF-36), Work Productivity and Activities Impairment -General Health (WPAI-GH) and Beck Depression Inventory-II (BDI-II) at 4 weeks, 6 months and 12 months relative to baseline</description>
        <time_frame>4 weeks, 6 months and 12 months</time_frame>
        <posting_date>11/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Measure</title>
        <description>Treatment Satisfaction Questionnaire for Medication (TSQM) scores at 4 weeks and change in TSQM scores at 6 months and 12 months versus baseline</description>
        <time_frame>6 months and 12 months</time_frame>
        <posting_date>11/2021</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum and Cerebrospinal Fluid Immune Markers</title>
        <description>Change in levels of serum and cerebrospinal fluid immune markers at 4 weeks, 6 months and 12 months versus baseline</description>
        <time_frame>4 weeks, 6 months and 12 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>H.P. Acthar Gel</title>
          <description>H.P. Acthar Gel: 80 IU subcutaneously daily for 10 days then followed by 80 IU subcutaneously three times per week through Month 12</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Horea Rus</name_or_title>
      <organization>UMaryland</organization>
      <phone>410-706-3170</phone>
      <email>hrus@som.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

